Kala Pharmaceuticals, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.18
FAIR PRICE
$1.20
MARGIN
$0.02
P/E Ratio
N/A
Div. Yield
N/A
ROE
-12955.6%
Average
Market Cap
$30M
Small-cap
NOW AVAILABLE
Get notified when KALA's fair price changes
Push notifications when KALA's valuation shifts. Available on iOS and Android.
FPI RATING
Low debt levels, but expensive valuation relative to fundamentals and volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$0.96
Fair price × 0.80
DISTANCE
18.3%
Price to entry level
At the current price of $1.18, KALA trades 18.3% above the conservative entry level of $0.96. This entry level represents a 20% margin of safety below the calculated fair price of $1.20 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate KALA's fair price
Kala Pharmaceuticals, Inc.'s fair price of $1.20 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.18, KALA trades 2.1% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting KALA's risk profile.
RELATIVE · 30%
Comparing KALA's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for KALA, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate KALA's fair value with your own inputs.
KALA DCF Calculator
Pre-filled with KALA's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter KALA's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of KALA's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare KALA against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for KALA.
Explore on BuliosFAQ
What is the fair price of KALA?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Kala Pharmaceuticals, Inc. is $1.20. At the current market price of $1.18, KALA trades 2.1% below its calculated fair value.
Is KALA overvalued or undervalued?+
Kala Pharmaceuticals, Inc. is currently fair based on our valuation model. The stock trades at $1.18, which is 2.1% below the fair price of $1.20.
What is the margin of safety for KALA?+
With a 20% margin of safety applied to the fair price of $1.20, the conservative entry level for KALA is $0.96. At the current market price of $1.18, the stock trades 18.3% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is KALA's fair price updated?+
We update fair price calculations for KALA daily after market close. The current fair price of $1.20 incorporates the latest market data and sector multiples.
What factors affect KALA's fair price calculation?+
KALA's fair price of $1.20 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -12955.6%.
Is KALA a good buy right now?+
At $1.18, KALA trades 2.1% below our fair value estimate of $1.20. The stock is currently fair. ROE stands at -12955.6% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does KALA pay dividends?+
KALA does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.